Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
NEWARK, Calif., May 16, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in a fireside chat at the 2017 UBS Global Healthcare Conference scheduled for 10:00 am ET (7:00 am PT) on Tuesday, May 23, 2017 in New York, New York.
This presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
